CRC Research Update — July 31, 2026
Today's colorectal cancer research highlights
crc-research
A collection of 364 issues
Physical activity and sedentary behavior linked to cortisol rhythms in CRC survivors up to 1 year after treatment
Skip to content
The CRC Digest
♥ LIVING WITH CRC
Physical activity and sedentary behavior linked to cortisol rhythms in CRC survivors up to 1 year after treatment
Among 74 CRC survivors, accelerometer-assessed sedentary time and physical activity were longitudinally associated with diurnal cortisol patterns, which may influence fatigue, mood, and
Case report: BRAF V600E-mutant metastatic CRC patient achieves prolonged response to combined BRAF and MEK inhibition
Skip to content
The CRC Digest
▸ TREATMENT
Case report: BRAF V600E-mutant metastatic CRC patient achieves prolonged response to combined BRAF and MEK inhibition
A 60-year-old male patient diagnosed in 2019 with BRAF-mutant metastatic CRC and peritoneal metastases experienced an extraordinary response to MEK inhibitor-based treatment. (Frontiers in Oncology)
This content
Gut microbiome signatures show promise for non-invasive detection of colorectal neoplasia
Skip to content
The CRC Digest
▪ SCREENING
Gut microbiome signatures show promise for non-invasive detection of colorectal neoplasia
Multinational metagenomic studies have identified reproducible microbial signatures associated with CRC, offering a potential alternative to current stool-based tests that have limited sensitivity for adenoma detection. (Journal of Gastroenterology)
This content is
Preclinical study shows fruquintinib combined with TAS-102 has antitumor activity in colorectal and gastric cancer models
Skip to content
The CRC Digest
▸ TREATMENT
Preclinical study shows fruquintinib combined with TAS-102 has antitumor activity in colorectal and gastric cancer models
Fruquintinib, an oral inhibitor of all three vascular endothelial growth factor receptors that has been approved for chemorefractory CRC, showed combined antitumor activity with TAS-102 in xenograft
Immunotherapy produces durable responses in dMMR/MSI-H metastatic CRC patients with poor performance status
Skip to content
The CRC Digest
◆ TRIAL DATA
Immunotherapy produces durable responses in dMMR/MSI-H metastatic CRC patients with poor performance status
Research shows that patients with deficient mismatch repair or high microsatellite instability can benefit from immunotherapy even when they have poor performance status, a group often excluded from
Phase 3 FIND trial shows ctDNA-guided surveillance detects recurrence earlier than standard CT scans after curative surgery
Skip to content
The CRC Digest
▪ SCREENING
Phase 3 FIND trial shows ctDNA-guided surveillance detects recurrence earlier than standard CT scans after curative surgery
The randomized trial found that circulating tumor DNA methylation monitoring identified recurrent metastatic disease with a more favorable and potentially resectable anatomical profile, significantly increasing the
CRC Research Update — July 30, 2026
Today's colorectal cancer research highlights
KRAS mutations drive immune evasion through RNA modifications
Skip to content
The CRC Digest
◇ RESEARCH
KRAS mutations drive immune evasion through RNA modifications
Preclinical research found that KRAS mutations remodel RNA m6A modifications to increase CD73 expression, promoting immune evasion in colorectal cancer. (Cancer Research)
This content is informational only and does not constitute medical advice.
Always consult
Liquid biopsy may guide HER2-targeted therapy rechallenge in metastatic disease
Skip to content
The CRC Digest
▸ TREATMENT
Liquid biopsy may guide HER2-targeted therapy rechallenge in metastatic disease
Real-world data suggest that monitoring HER2 amplification through liquid biopsy can help identify patients with HER2-amplified metastatic colorectal cancer who may benefit from rechallenge with anti-HER2 therapy. (JCO Precision Oncology)
This content is